Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.
Vivos Therapeutics Inc (VVOS) Stock: More Resilient Than It Appears
In recent trading, Vivos Therapeutics Inc (VVOS) stock price has shown some volatility, fluctuating 4.41% over the last five trades and 8.57% over the past 30 trades. This represents a notable shift from earlier in the year.
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.13 on Wednesday. The stock is down almost 76% this year.
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics Offers Of 1.363 Mln Shares At $3.15/share, Pre-Market Stock Down
Vivos Therapeutics, Inc. (VVOS), a medical device and technology company, announced on Thursday that it has inked a deal with
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults),
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
MarketWatch5d
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment
Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration.
Investing4d
Vivos Therapeutics announces $4.3 million stock sale
LITTLETON, Colo. - Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company specializing in treatments for sleep-related breathing disorders, has entered into agreements with ...
Benzinga.com5d
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Vivos believes this breakthrough regulatory clearance represents a huge opportunity to capture significant market share. Recent published studies report up to 10.1 million U.S. children (ages 6-17 ...